Skip to main content

Arymo ER FDA Approval History

FDA Approved: Yes (Discontinued) (First approved January 9, 2017)
Brand name: Arymo ER
Generic name: morphine sulfate
Dosage form: Extended-Release Tablets
Company: Egalet Corporation
Treatment for: Pain

Marketing Status: Discontinued

Arymo ER (morphine sulfate) is an extended-release, abuse-deterrent, opioid analgesic formulation for the management of severe pain.

Development timeline for Arymo ER

Jan  9, 2017Approval FDA Approves Arymo ER (morphine sulfate) Abuse-Deterrent Formulation for the Treatment of Chronic Pain
Oct 13, 2016Egalet Notified that FDA Will Not Meet PDUFA Goal Date for Arymo ER
Aug  4, 2016Egalet Announces FDA Advisory Committees Recommend Approval of Abuse-Deterrent Arymo ER (Morphine Sulfate)
Feb 29, 2016Egalet Announces FDA Acceptance of New Drug Application for Arymo ER (Morphine Sulfate) Extended-Release Tablets
Dec 15, 2015Egalet Submits NDA for Arymo ER (Morphine Sulfate) Extended-Release Tablets

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.